Drug Profile


Latest Information Update: 18 Jun 2001

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antiglaucomas; Antihypertensives
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Arrhythmias; Glaucoma; Hypertension; Ischaemic heart disorders; Retinal disorders

Most Recent Events

  • 18 Jun 2001 No-Development-Reported for Retinal disorders in USA (Unknown route)
  • 18 Jun 2001 No-Development-Reported for Glaucoma in USA (Unknown route)
  • 23 Apr 1997 No-Development-Reported for Hypertension in Taiwan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top